Literature DB >> 17187486

Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.

Sanja Dacic1.   

Abstract

The overall survival of patients with lung cancer is dismal despite extensive effort in improvement of diagnosis and treatment. A better understanding of the multistep genetic and epigenetic alterations in lung cancer pathogenesis and progression is necessary for development of improved diagnostic approaches and new targeted therapies. Identification of molecular alterations in the early lung carcinogenesis, together with advanced molecular techniques, may facilitate development of rapid and effective methods for early diagnosis and prognosis of lung carcinoma. In this review, we discuss current understanding of lung carcinogenesis and prospective molecular markers in lung cancer diagnosis. Although the impact of translating new technologies into clinical practice on survival has not been completely determined, they offer a new avenue of exciting novel approaches to early diagnosis of this deadly disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17187486     DOI: 10.1586/14737159.7.1.77

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  3 in total

Review 1.  The emerging role of microRNAs in drug responses.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Curr Opin Mol Ther       Date:  2010-12

2.  Genetics of a combined lung small cell carcinoma and large cell neuroendocrine carcinoma with adenocarcinoma.

Authors:  Giovanni Fellegara; Tiziana D'Adda; Francesco P Pilato; Elisabetta Froio; Luca Ampollini; Michele Rusca; Guido Rindi
Journal:  Virchows Arch       Date:  2008-06-13       Impact factor: 4.064

3.  The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.

Authors:  Jun Jia; Pengfei Zhang; Miaomiao Gou; Fan Yang; Niansong Qian; Guanghai Dai
Journal:  Dis Markers       Date:  2019-01-20       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.